NF2associated

NF2associated refers to the tumors and clinical features that arise in Neurofibromatosis Type 2 (NF2), a dominantly inherited tumor predisposition caused by pathogenic variants in the NF2 gene on chromosome 22. The NF2 gene encodes merlin (schwannomin), a tumor suppressor protein involved in regulating cell growth and contact inhibition. When the second NF2 allele is inactivated in susceptible tissues, tumor development occurs.

The hallmark NF2-associated tumor is bilateral vestibular schwannoma, leading to progressive hearing loss and balance disturbance. Other common NF2-associated tumors include intracranial and spinal meningiomas, schwannomas of other cranial nerves, and ependymal tumors of the spinal cord. Less frequently observed features include juvenile cataracts and various skin lesions. The combination and early appearance of these tumors help distinguish NF2-associated disease from sporadic tumors.

Genetically, NF2 disease is autosomal dominant with high penetrance but variable expressivity. About half of cases arise from germline pathogenic variants; somatic mosaicism can occur, producing segmental or milder phenotypes. Tumorigenesis typically involves loss of the remaining functional NF2 allele in Schwann cells and other susceptible tissues.

Diagnosis combines clinical criteria with imaging and genetic testing. Magnetic resonance imaging is used to monitor the brain and spine, and audiology assessments track hearing function. Management is multidisciplinary, including surgical resection or radiosurgery for tumors when indicated, hearing preservation strategies, and treatment of symptoms. Experimental therapies targeting merlin signaling and related pathways are under investigation.

Prognosis varies with tumor burden, onset age, and treatment response, necessitating ongoing, individualized care and surveillance for NF2-associated disease.